Startups
The Investor Relations website contains information about AVEO Oncology's business for stockholders, potential investors, and financial analysts.
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 4, 2023 | Biotech investor Brad Loncar shares 10 predictions for 2023, including a hot new cancer target, Nobel Prize winners, and a biotech founder running for president | Brad Loncar, biotech investor and CEO of Loncar Investments Brad Loncar This story is available exclusively to Insider subscribers. Become an Insider and start reading now. For the third straight year with Insider, biotech investor Brad Lon... |
| Mar 16, 2021 | AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update | BOSTON--(BUSINESS WIRE)--Mar 16, 2021-- AVEO Oncology (Nasdaq: AVEO) today reported financial results for the full year ended December 31, 2020 and provided a business update. “The U.S. Food and Drug Administration’s (FDA) recent approval o... |
| Apr 3, 2019 | After falling short on prelim OS data, EMA tells Aveo it wants to see something better on its long suffering tivo this summer — or else | When Aveo Oncology scored European approval in 2017 for its lead cancer drug tivozanib — despite the treatment’s chequered past — a comeback story was in the making. New pivotal data could now threaten that approval, and th... |